Blueprint Medicines Corporation

(BPMC) Trade

By |

Profile

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.

Contact Information

Website: www.blueprintmedicines.com
Email: hannahd@sternir.com
Main Phone: +1 617 374-7580
Address: 45 Sidney Street
Address 2: Suite 3500
State: MA
City / Town: Cambridge
Country: USA
Postal Code: 02139

Issuer Information

Exchange: NGS
CEO: Jeffrey W. Albers
Employees: 153
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 71.62 $ 0. (0.00%)
Last Price 71.62 Change $ 0. Change % 0.00 Tick N/A
Bid 60.00 Bid Size 1,000.00 Ask 78.00 Ask Size 400.00
Open 72.25 High 73.74 Low 71.08 Prev Close 71.62
Last Trade Volume 223,226 52 Wk Hi 109.00 52 Wk Low 57.44
Market Cap 3.1 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 43,887,732.00 EPS (TTM) -4.12 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 12 111
Number of Buys 3 21
Number of Sells 9 90
Net Activity -5492 -163354
Last 10 Buys Shares
N/A 0
Last 10 Sell Shares
Alexis Borisy 1,000
Alexis Borisy 1,000
Alexis Borisy 1,000
Alexis Borisy 1,000
Jeffrey W. Albers 1,000
Jeffrey W. Albers 1,000
Alexis Borisy 1,000
George D. Demetri 1,000
George D. Demetri 1,000
George D. Demetri 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 113 113 113 113
Low Target Price Estimate 66 66 66 66
Mean Target Price Estimate 94.83 93.2 93.2 94.83
Standard Deviation 16.07 17.4 17.4 16.07
Date of Most Recent Estimate 06/04/18 05/17/18 05/17/18 06/04/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 6 5 5 5
Moderate Buy 1 1 2 2
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.14 1.17 1.21 1.21